Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT06483139
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Plasma exchange — PROCEDURE
    Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
  • Daratumumab — DRUG
    Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy

Study Details

Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus daratumumab-based regimens versus non-daratumumab based-regimens.

Key Dates

First listed
Jul 3, 2024
Start date
Jun 1, 2024
Status verified
Jul 2026
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
549 participants (actual)

Arms

  • Arm: Patients treated with plasma exchange
    Treated with plasma exchange ithin 30 days of diagnosis of light chain cast nephropathy
  • Arm: Patients not treated with plasma exchange
    Patients not treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy
  • Arm: Patients treated with daratumumab
    Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
  • Arm: Patients not treated with daratumumab
    Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy

Primary Outcome Measure

The primary composite outcome is the rate of survival with renal recovery within 90 days from the diagnosis of light chain cast nephropathy. [ Time Frame: 90 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02130-

Find similar trials in Boston, MA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Brigham and Women's Hospital· Boston, MA

Related Studies